


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>Applicant(s):</i>	Benameur <i>et al.</i>	<i>Confirmation No.:</i>	9192
<i>Serial No.:</i>	10/764,282	<i>Group Art Unit:</i>	1609
<i>Filed:</i>	January 23, 2004	<i>Examiner:</i>	Aradhana, Sasan
<i>Docket No.:</i>	1759.051A	<i>Submission Date:</i>	June 13, 2007
<i>Title:</i>	PHARMACEUTICAL COMPOSITION FOR ORAL USE COMPRISING AN ACTIVE PRINCIPLE LIABLE TO UNDERGO A LARGE FIRST INTESTINAL PASSAGE EFFECT		

To: Commissioner for Patents (Amendments)
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope or is transmitted by electronic filing to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 13, 2007.



Erika L. Senska
Attorney for Applicant(s)

Reg. No.53,312

Date of Signature: June 13, 2007

RESPONSE TO OFFICE ACTION

Dear Sir:

This is a Response to the Non-Final Office Action mailed February 13, 2007. In light of a request for a one-month extension and fee thereof, enclosed herewith, Response is required by June 13, 2007, therefore this response is timely filed.

Amendments to the specification begin on page 2.

Amendments to the claims begin on page 3.

Remarks begin on page 6.